Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Anti-tumor Activity of Toll-Like Receptor 7 Agonists.

Chi H, Li C, Zhao FS, Zhang L, Ng TB, Jin G, Sha O.

Front Pharmacol. 2017 May 31;8:304. doi: 10.3389/fphar.2017.00304. eCollection 2017. Review.

2.

Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract.

Spanou E, Kalisperati P, Pateras IS, Papalampros A, Barbouti A, Tzioufas AG, Kotsinas A, Sougioultzis S.

Front Genet. 2017 May 29;8:65. doi: 10.3389/fgene.2017.00065. eCollection 2017. Review.

3.

Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer.

Maitra R, Augustine T, Dayan Y, Chandy C, Coffey M, Goel S.

Oncotarget. 2017 May 23;8(21):35138-35153. doi: 10.18632/oncotarget.16812.

4.

Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth.

Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S.

Nat Commun. 2017 Mar 16;8:14600. doi: 10.1038/ncomms14600.

5.

Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.

Seth A, Lee H, Cho MY, Park C, Korm S, Lee JY, Choi I, Lim YT, Hong KS.

Oncotarget. 2017 Jan 17;8(3):5371-5381. doi: 10.18632/oncotarget.14260.

6.

The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines.

Patchett AL, Darby JM, Tovar C, Lyons AB, Woods GM.

PLoS One. 2016 Dec 9;11(12):e0168068. doi: 10.1371/journal.pone.0168068. eCollection 2016.

7.

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.

Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE.

Immunotargets Ther. 2015 May 15;4:91-100. doi: 10.2147/ITT.S61292. eCollection 2015. Review.

8.

Therapeutic cancer vaccines and combination immunotherapies involving vaccination.

Nguyen T, Urban J, Kalinski P.

Immunotargets Ther. 2014 Oct 6;3:135-50. doi: 10.2147/ITT.S40264. eCollection 2014. Review.

9.

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Sep 2;5(3):e1088631. eCollection 2016 Mar. Review.

10.

Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4.

Yang J, Qin N, Zhang H, Yang R, Xiang B, Wei Q.

Sci Rep. 2016 Apr 19;6:24346. doi: 10.1038/srep24346.

11.

Trial Watch: Adoptive cell transfer for oncological indications.

Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 May 5;4(11):e1046673. eCollection 2015 Nov. Review.

12.

4T1 Murine Mammary Carcinoma Cells Enhance Macrophage-Mediated Innate Inflammatory Responses.

Madera L, Greenshields A, Coombs MR, Hoskin DW.

PLoS One. 2015 Jul 15;10(7):e0133385. doi: 10.1371/journal.pone.0133385. eCollection 2015.

13.

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S.

Oncoimmunology. 2015 Mar 19;4(5):e1001236. eCollection 2015 May. Review.

14.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

15.

Trial watch: IDO inhibitors in cancer therapy.

Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 15;3(10):e957994. eCollection 2014 Nov. Review.

16.

Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma.

Farnebo L, Shahangian A, Lee Y, Shin JH, Scheeren FA, Sunwoo JB.

Oncotarget. 2015 Apr 30;6(12):9897-907.

17.

Targeting the tumor microenvironment to enhance antitumor immune responses.

Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K.

Oncotarget. 2015 Jan 30;6(3):1359-81. Review.

18.

Three steps to breaking immune tolerance to lymphoma: a microparticle approach.

Makkouk A, Joshi VB, Lemke CD, Wongrakpanich A, Olivier AK, Blackwell SE, Salem AK, Weiner GJ.

Cancer Immunol Res. 2015 Apr;3(4):389-98. doi: 10.1158/2326-6066.CIR-14-0173. Epub 2015 Jan 27.

19.

Serum toll-like receptors are potential biomarkers of radiation pneumonia in locally advanced NSCLC.

Lan F, Yue X, Ren G, Wang Y, Xia T.

Int J Clin Exp Pathol. 2014 Oct 15;7(11):8087-95. eCollection 2014.

20.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

Supplemental Content

Support Center